Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2016 / Feb / Diversity’s Double-Edged Sword
Microbiology & Immunology Microbiology and Immunology Biochemistry and molecular biology Molecular Pathology

Diversity’s Double-Edged Sword

H. pylori’s attachment protein allows it to adhere to multiple blood group antigens – but also contains a disulfide-clasped loop that may be its downfall

By Michael Schubert 02/25/2016 1 min read

Share

Helicobacter pylori is a well-known culprit in cases of gastritis, peptic ulcer and gastric cancer. The bacterium is able to survive the acidic stomach environment by attaching itself tightly to the epithelial cells of the gastric mucosa – a key mechanism in the establishment of chronic infection and mucosal inflammation. In the 90s, Borén identified the ABO blood group antigens as binding sites for the H. pylori BabA adhesin in the gastric cell lining (1)(2). Vaccine development has so far shown limited progress, and although H. pylori is one of the most prevalent infection in humans, antibiotic therapy is restricted because of the risk of resistance and therefore only recommended for use against peptic ulcers. With no way of identifying the patients at greatest risk of stomach cancer, and only poor ways of fighting the disease once it develops, there’s an urgent need to develop new therapies against H. pylori infection. Fortunately, a team of researchers in Belgium and Sweden have uncovered what they deem the bacterium’s Achilles heel: a weakness in the binding protein BabA (3).

Thomas Borén, who led the Swedish contingent, explains that BabA binds to the ABO blood group glycans presented on the gastrointestinal epithelial cells (4): “In the stomach, H. pylori manage to adapt extensively to changes in the stomach such as during chronic inflammation.” He and his team have determined that BabA is extensively polymorphic due to adaptation (4). By crystallization of the protein, Han Remaut’s team in Brussels could show that the functional polymorphism is owing to two diversity loops inside the protein’s glycan binding site, whose amino acid sequences can be changed to alter binding properties, such as blood group preference. But at the same time, the teams discovered that the binding “holdfast” in the BabA protein is formed by a disulfide-clasped loop that can be inactivated by reduction – providing hopes that the source of the bacterium’s strength may also be the source of its defeat.  “The possibilities we now have uncovered to specifically interfere with H. pylori adherence and reduce the intensity of the chronic inflammation processes are exceedingly exciting,” says Remaut, “especially since this does not involve the use of broad-range antibiotics that are known to have undesired collateral impact on the healthy microbiota.” Instead, the two teams propose to treat infections using redox-active drugs that inactivate the disulfide-clasped loop, causing difficulties only to H. pylori (see Figure 1). “This could open the door to a new type of antimicrobial drugs,” says Remaut. “The structural information also provides promising possibilities for how to develop novel vaccines against adherent H. pylori infections, says Borén. The two teams are currently studying the way H. pylori adapts to changes in the stomach during disease progression, and they anticipate that better understanding of the H. pylori attachment processes will also help epidemiological studies. MS

Figure 1. Close up view of the BabA protein’s glycan binding site in complex with Lewis B, its main blood group antigen receptor in the stomach epithelium. Shown is a superimposition of the BabA proteins from four clinical isolates, highlighting the diversity inside the binding pocket. Redox-active pharmaceuticals such as N-Acetylcysteine (NAC) disrupt the conserved cys-clasped loop in the binding pocket (boxed area), and lead to the loss of H. pylori adherence to the stomach epithelium (see bar graph).

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. T Borén et al., “Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens”, Science, 262, 1892–1895 (1993). PMID: 8018146. D Ilver et al., “Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging”, Science, 16, 373–377 (1998). PMID: 9430586. K Moonens et al., “Structural insights into polymorphic ABO glycan binding by Helicobacter pylori”, Cell Host Microbe, 19, 55–66 (2016). PMID: 26764597. M Aspholm-Hurtig et al., “Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin”, Science, 23, 519–522 (2004). PMID: 15273394.

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Context Matters in Cancer Biology
Microbiology and Immunology
Context Matters in Cancer Biology

December 27, 2021

1 min read

Akoya is leading the way with spatial phenotypic signatures – a novel class of biomarkers for predicting response to immunotherapy

What’s New in Infectious Disease? (December 2021)
Microbiology and Immunology
What’s New in Infectious Disease?

December 23, 2021

1 min read

The latest research and news on COVID-19 and the infectious disease landscape

Immunology Insights
Microbiology and Immunology
Immunology Insights

January 13, 2022

1 min read

The latest research in pathology and laboratory medicine

2021: A Laboratory Medicine Roundup
Microbiology and Immunology
2021: A Laboratory Medicine Roundup

January 18, 2022

3 min read

From transgender health care to the power of pathology podcasts, we take a look at our most popular articles of the last year

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.